Lawsuit concerns Teva's application for approval to market Levitra for the treatment of erectile dysfunction
Multaq to treat patients with atrial fibrillation or atrial flutter
Dow To Streamline Manufacturing Footprint
Calls for shutdown of a number of manufacturing assets, including ethylene and ethylene-derivative assets
Myriad Genetics Spins Off Research, Pharmaceutical Business
Myriad Genetics to claim approximately $400 million in tax deductions
GSK Extends Product Portfolio In Middle East, North Africa
Business comprises a portfolio of 13 branded pharmaceuticals
Biogen Idec, Acorda Sign Collaboration Agreement For Fampridine-SR
Acorda to continue developing and commercializing Fampridine-SR in the US
Graceway Signs Acquisition, License Agreement With Pfizer
Graceway to acquire worldwide commercial rights for three investigational dermatological molecules from Pfizer
Morphotek Signs Collaboration Agreement With Synageva
To develop therapeutic monoclonal antibodies for treatment of various forms of cancer and infectious disease
Sepracor Provides Update On Clinical Trials For SEP-225289, Lunesta
SEP-225289 did not meet the primary efficacy endpoint, but Lunesta has been proven to be safe and well tolerated
Shire Provides Results For Phase 3b Vyvanse Study
Vyvanse improved the ability to focus and organize, as well as hyperactivity and impulsivity
Schering-Plough Presents Phase II and III Data For Corifollitropin Alfa
Corifollitropin Alfa provides treatment in Controlled Ovarian Stimulation for development of multiple follicles in women